viewTiziana Life Sciences PLC

Tiziana Life Sciences upbeat on potential for coronavirus treatment


  • US and UK listed biotech with three key monoclonal antibody treatments
  • Has applied for a patent for possible coronavirus treatment
  • Other products target liver cancer and autoimmune diseases
Tiziana Life Sciences - Tiziana Life Sciences upbeat on potential for coronavirus treatment

Quick facts: Tiziana Life Sciences PLC

Price: 152 GBX

Market: AIM
Market Cap: £295.81 m

How it is doing

Shares have soared recently on the potential for Tiziana’s (LON:TILS) TZLS-501 to be useful for people severely ill with coronavirus-related complications.

TZLS-501 is a class of monoclonal antibody (mAb) called an anti-interleukin-6 receptor, or anti-IL6R for short.

In November, it began a clinical study of the drug administered either alone or in combination with dexamethasone, a corticosteroid medication.  

The day-to-day work is coordinated by the team at the INTRIALS, a clinical research organization based in Sao Paulo, Brazil.

Other drugs in development 

Also in November, the AIM-listed firm started preparing to embark on a clinical study of what would be the first orally-taken home treatment for Crohn’s Disease using a monoclonal antibody.

It is collaborating with Parexel Biotech, a subsidiary of the contract research giant Parexel, to conduct the phase Ib/II trial of a coated pill containing Foralumab, a fully-human mAb.

In doing so, researchers from Europe and the US will assess for safety, tolerability and clinical activity of escalating doses of the treatment.


Read: initiation note on Tiziana Life Sciences: Transformational potential


What the boss says: Howard Weiner, head of Tiziana’s scientific advisory board

“We believe the scientific rationale for oral treatment with Foralumab is logical to facilitate topical action at the inflamed sites in the gastrointestinal tract. This potentially ground-breaking approach for immunotherapies originated in my laboratory and was subsequently reported by other researchers in the field."




Inflexion points

  • Clinical trials for coronavirus treatment
  • Nasally administered Chron's Disease treatment


Read the latest research update: Expanding the pipeline, unlocking value


What the broker says

HC Wainwright, a Wall Street investment bank which rates the firm a ‘buy’ up to US$11, said in September it sees “meaningful upside” to its valuation of Tiziana Life Sciences.

“We note that our current valuation does not include any contribution from the use of foralumab to treat COVID-19-infected patients.

“Thus, if the Brazilian trial proves successful, this could constitute meaningful upside to our estimates.”

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...


Market Report: Happy new year, happy new vaccine as AstraZeneca/Oxford...

FTSE 100 opened with a jump in the first trading day of the new year although coronavirus infections continue to surge. London’s main index added 120 points to 6,580 in early trading. The UK has begun the rollout of the COVID-19 vaccine produced by AstraZeneca PLC (LON:AZN) and Oxford...

1 week, 6 days ago

2 min read